1-[6-(4-Fluoro-benzyl)-3,3-dimethyl-2,3-dihydro-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2R,5R)-5-methyl-2-((R)-3-methyl-morpholin-4-ylmethyl)-piperazin-1-yl]-ethanone dihydrochloride → AT-Iap
反応式
Cl.Cl.[F:3][C:4]1[CH:39]=[CH:38][C:7]([CH2:8][C:9]2[CH:10]=[C:11]3[N:17]([C:18](=[O:35])[CH2:19][N:20]4[CH2:25][C@@H:24]([CH3:26])[NH:23][CH2:22][C@@H:21]4[CH2:27][N:28]4[CH2:33][CH2:32][O:31][CH2:30][C@H:29]4[CH3:34])[CH2:16][C:15]([CH3:37])([CH3:36])[C:12]3=[N:13][CH:14]=2)=[CH:6][CH:5]=1>O>[F:3][C:4]1[CH:39]=[CH:38][C:7]([CH2:8][C:9]2[CH:10]=[C:11]3[N:17]([C:18](=[O:35])[CH2:19][N:20]4[CH2:25][C@@H:24]([CH3:26])[NH:23][CH2:22][C@@H:21]4[CH2:27][N:28]4[CH2:33][CH2:32][O:31][CH2:30][C@H:29]4[CH3:34])[CH2:16][C:15]([CH3:37])([CH3:36])[C:12]3=[N:13][CH:14]=2)=[CH:6][CH:5]=1参加物
実験手順
1-[6-(4-Fluoro-benzyl)-3,3-dimethyl-2,3-dihydro-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2R,5R)-5-methyl-2-((R)-3-methyl-morpholin-4-ylmethyl)-piperazin-1-yl]-ethanone dihydrochloride (1.8 g) was dissolved in water (50 mL) and the resulting solution extracted with ethyl acetate (50 mL). The aqueous phase was basified (pH 8) with saturated aqueous NaHCO3 then was extracted with DCM (5×50 mL). The combined DCM extracts were dried (Na2SO4) and evaporated in vacuo to give the title compound (1.72 g) as a foam. 1H NMR (Me-d3-OD): 8.24 (1H, s), 8.07 (1H, d), 7.24 (2H, dd), 7.03 (2H, t), 4.19-4.06 (1H, m), 3.99 (3H, d), 3.90 (1H, d), 3.71 (1H, d), 3.65-3.48 (2H, m), 3.19-2.70 (8H, m), 2.60-2.40 (2H, m), 2.26 (1H, s), 2.09-1.93 (1H, m), 1.87 (1H, d), 1.41 (6H, d), 1.04 (3H, d), 0.97 (3H, d).
後処理
- extractionthe resulting solution extracted with ethyl acetate (50 mL)
- extractionthen was extracted with DCM (5×50 mL)
- dry with materialThe combined DCM extracts were dried (Na2SO4)
- customevaporated in vacuo
出典と根拠
- ORDレコード
- ord-ac26ab26d0c442e7a458146e1686ff50
- 出典データセット
- uspto-grants-2015_04
- 特許番号
- US09018214B2
反応ノート
読み込み中…